## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.2% below STRENGTH zone (4.0-10.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($554.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Thermo Fisher Expands BioProcessing in Asia**
- Source: Powder & Bulk Solids | 20251210T014456 | Bullish | Relevance: 99%
-  Thermo Fisher Scientific is expanding its bioprocessing capabilities across Asia to support the region's growing biopharmaceutical industry. The company is opening a new Bioprocess Design Center in Hyderabad, India, and has expanded existing centers in Incheon, Korea, and Singapore. This strategic network aims to enhance speed, efficiency, and sustainability in biomanufacturing while providing localized support and access to advanced technologies.

**2. Thermo Fisher upgraded at Citi on boost in pharma spending**
- Source: Seeking Alpha | 20251211T160857 | Bullish | Relevance: 99%
- Citi has upgraded Thermo Fisher Scientific (TMO) to a "buy" rating from "neutral." The upgrade is based on the expectation that Thermo Fisher will benefit from increased R&D spending by pharmaceutical companies. This anticipated boost in pharma spending is attributed to new clarity on drug pricing following recent industry deals.

**3. Natixis Has $23.43 Million Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251209T132304 | Bullish | Relevance: 98%
- Natixis significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.6% in the second quarter, bringing its holding to 57,783 shares valued at $23.43 million. Other institutional investors also adjusted their positions in the medical research company, which recently reported strong earnings and announced a quarterly dividend of $0.43 per share. Wall Street analysts maintain a "Moderate Buy" rating for TMO, with a consensus price target of $612.95.

**4. Thermo Fisher Expands Bioprocess Design Centers Across Asia**
- Source: Lab Manager | 20251209T200855 | Bullish | Relevance: 98%
- Thermo Fisher Scientific has expanded its bioprocess design center network in Asia by adding a new facility in Hyderabad, India, and enlarging existing centers in Incheon, Korea, and Singapore. These centers will provide localized access to bioprocessing capabilities, specialized expertise, and infrastructure to accelerate the development of biologics and advanced therapies. The expansion aims to shorten development timelines, provide agile technical support, and help laboratory managers make informed decisions regarding instrumentation, workflow design, and scalability.

**5. Q4 Earnings Estimate for TMO Issued By KeyCorp**
- Source: MarketBeat | 20251209T133338 | Bullish | Relevance: 98%
-  KeyCorp analysts have issued their Q4 2025 earnings per share estimate for Thermo Fisher Scientific (NYSE: TMO) at $6.48, maintaining an "Overweight" rating and a $750.00 price target. This comes alongside other analyst updates, with a consensus "Moderate Buy" rating and an average price target of $612.95 for the company. Thermo Fisher Scientific recently reported Q3 earnings of $5.79 per share, beating consensus estimates, and announced a quarterly dividend and a $5.00 billion share repurchase program.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Heavy insider selling: $42M sold (14 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.5B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 23.5 |
| Current P/E | 25.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.7% to -2.2% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-2.94), momentum weakening. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.19% (CS: 28) | Weak |
| RSI_14 | 54.5 | Neutral |
| MACD Histogram | -2.94 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.202x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $578.90
- **Stop Loss:** $554.20 (4.3% risk)
- **Target:** $603.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 55
- **Position Value:** $31,839.50
- **Portfolio %:** 31.84%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*